Annual ROE
353.89%
-451.32%-56.05%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual return on equity is currently 353.89%, with the most recent change of -451.32% (-56.05%) on 31 December 2023. During the last 3 years, it has risen by +443.59% (+494.53%). BCLI annual ROE is now -56.05% below its all-time high of 805.21%, reached on 31 December 2022.BCLI ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
284.67%
-24.01%-7.78%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly return on equity is currently 284.67%, with the most recent change of -24.01% (-7.78%) on 30 September 2024. Over the past year, it has dropped by -179.94% (-38.73%). BCLI quarterly ROE is now -99.59% below its all-time high of 69.06 thousand%, reached on 30 June 2020.BCLI Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.0% | -38.7% |
| 3 y3 years | +494.5% | +399.9% |
| 5 y5 years | +227.3% | -79.8% |
BCLI ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -56.0% | +379.9% | -66.9% | +104.1% |
| 5 y | 5 years | -56.0% | +227.3% | -99.6% | +104.1% |
| alltime | all time | -56.0% | +113.2% | -99.6% | +101.0% |
Brainstorm Cell Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | 284.67%(-7.8%) |
| June 2024 | - | 308.68%(-16.2%) |
| Mar 2024 | - | 368.28%(-13.4%) |
| Dec 2023 | 353.89%(-56.0%) | 425.49%(-8.4%) |
| Sept 2023 | - | 464.61%(-46.0%) |
| June 2023 | - | 860.53%(-112.4%) |
| Mar 2023 | - | -6929.48%(+1377.9%) |
| Dec 2022 | 805.21%(-736.8%) | -468.87%(+98.4%) |
| Sept 2022 | - | -236.36%(+64.5%) |
| June 2022 | - | -143.69%(+38.0%) |
| Mar 2022 | - | -104.15%(+17.8%) |
| Dec 2021 | -126.45%(+41.0%) | -88.42%(-6.8%) |
| Sept 2021 | - | -94.92%(+3.7%) |
| June 2021 | - | -91.49%(-19.0%) |
| Mar 2021 | - | -113.00%(-28.7%) |
| Dec 2020 | -89.70%(-147.2%) | -158.51%(-53.4%) |
| Sept 2020 | - | -339.86%(-100.5%) |
| June 2020 | - | 69.06 K%(+9408.0%) |
| Mar 2020 | - | 726.37%(+81.1%) |
| Dec 2019 | 190.24%(-168.4%) | 401.09%(-71.5%) |
| Sept 2019 | - | 1407.76%(-305.7%) |
| June 2019 | - | -684.41%(+189.3%) |
| Mar 2019 | - | -236.61%(+34.4%) |
| Dec 2018 | -278.07%(+230.2%) | -175.99%(+72.9%) |
| Sept 2018 | - | -101.81%(-5.9%) |
| June 2018 | - | -108.21%(+9.9%) |
| Mar 2018 | - | -98.47%(+32.3%) |
| Dec 2017 | -84.22%(+67.4%) | -74.44%(-2.6%) |
| Sept 2017 | - | -76.42%(+35.9%) |
| June 2017 | - | -56.23%(+14.5%) |
| Mar 2017 | - | -49.10%(+10.6%) |
| Dec 2016 | -50.31%(-16.3%) | -44.41%(-5.1%) |
| Sept 2016 | - | -46.78%(-6.1%) |
| June 2016 | - | -49.83%(-7.0%) |
| Mar 2016 | - | -53.56%(+5.9%) |
| Dec 2015 | -60.08%(-56.6%) | -50.56%(-23.3%) |
| Sept 2015 | - | -65.90%(-9.4%) |
| June 2015 | - | -72.74%(-11.1%) |
| Mar 2015 | - | -81.78%(-40.2%) |
| Dec 2014 | -138.52%(-22.6%) | -136.80%(+2.2%) |
| Sept 2014 | - | -133.90%(-1.9%) |
| June 2014 | - | -136.52%(-39.6%) |
| Mar 2014 | - | -226.07%(+51.2%) |
| Dec 2013 | -178.86% | -149.47%(+25.9%) |
| Sept 2013 | - | -118.75%(-2.1%) |
| June 2013 | - | -121.29%(+1.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | -119.62%(-17.1%) |
| Dec 2012 | -86.14%(-67.3%) | -144.30%(-40.8%) |
| Sept 2012 | - | -243.64%(-21.9%) |
| June 2012 | - | -312.06%(+31.5%) |
| Mar 2012 | - | -237.22%(+32.2%) |
| Dec 2011 | -263.31%(-150.0%) | -179.38%(+2.1%) |
| Sept 2011 | - | -175.67%(-43.8%) |
| June 2011 | - | -312.40%(-65.3%) |
| Mar 2011 | - | -900.90%(-244.2%) |
| Dec 2010 | 527.02%(+415.8%) | 624.66%(+117.3%) |
| Sept 2010 | - | 287.47%(+75.8%) |
| June 2010 | - | 163.50%(+43.3%) |
| Mar 2010 | - | 114.06%(+42.2%) |
| Dec 2009 | 102.18%(-38.9%) | 80.19%(-19.8%) |
| Sept 2009 | - | 99.99%(-12.5%) |
| June 2009 | - | 114.32%(-18.8%) |
| Mar 2009 | - | 140.83%(-19.9%) |
| Dec 2008 | 167.24%(-35.0%) | 175.80%(-23.7%) |
| Sept 2008 | - | 230.34%(-9.6%) |
| June 2008 | - | 254.93%(+10.7%) |
| Mar 2008 | - | 230.38%(-7.0%) |
| Dec 2007 | 257.17%(+19.0%) | 247.64%(+45.7%) |
| Sept 2007 | - | 169.95%(+0.1%) |
| June 2007 | - | 169.73%(-22.6%) |
| Mar 2007 | - | 219.18%(+74.9%) |
| Dec 2006 | 216.08%(+415.3%) | - |
| Sept 2006 | - | 125.32%(-15.8%) |
| June 2006 | - | 148.92%(-16.7%) |
| Mar 2006 | - | 178.85%(-115.9%) |
| Mar 2006 | 41.93%(-101.6%) | - |
| Dec 2005 | - | -1122.13%(-77.0%) |
| Sept 2005 | - | -4879.76%(-14.4%) |
| June 2005 | - | -5700.44%(-24.0%) |
| Mar 2005 | -2674.21%(-1245.6%) | -7505.03%(-72.3%) |
| Dec 2004 | - | -27.11 K%(+187.7%) |
| Sept 2004 | - | -9420.89%(+961.7%) |
| June 2004 | - | -887.33%(-141.5%) |
| Mar 2004 | 233.44%(-280.8%) | 2140.15%(-477.5%) |
| Dec 2003 | - | -566.93%(+79.0%) |
| Sept 2003 | - | -316.77%(+53.8%) |
| June 2003 | - | -205.96%(+41.6%) |
| Mar 2003 | -129.08%(+163.2%) | -145.45%(+73.3%) |
| Dec 2002 | - | -83.93%(+97.3%) |
| Sept 2002 | - | -42.53%(+115.7%) |
| June 2002 | - | -19.72% |
| Mar 2002 | -49.04% | - |
FAQ
- What is Brainstorm Cell Therapeutics annual return on equity?
- What is the all time high annual ROE for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual ROE year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly ROE year-on-year change?
What is Brainstorm Cell Therapeutics annual return on equity?
The current annual ROE of BCLI is 353.89%
What is the all time high annual ROE for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual return on equity is 805.21%
What is Brainstorm Cell Therapeutics annual ROE year-on-year change?
Over the past year, BCLI annual return on equity has changed by -451.32% (-56.05%)
What is Brainstorm Cell Therapeutics quarterly return on equity?
The current quarterly ROE of BCLI is 284.67%
What is the all time high quarterly ROE for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly return on equity is 69.06 K%
What is Brainstorm Cell Therapeutics quarterly ROE year-on-year change?
Over the past year, BCLI quarterly return on equity has changed by -179.94% (-38.73%)